Clinical trials: Vinorelbine
Metastatic Breast Cancer, Recurrent Breast Cancer
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy.
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
- Trial name
- NCT06202261
- Testing
- TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer Metastatic
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
- Trial name
- NCT03321981
- Testing
- Zenocutuzumab, Trastuzumab, Vinorelbine
- Where
- 25 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Merus B.V.
HER2-positive Breast Cancer
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety and Immunogenicity of Vinorelbine Bitartrate Injection in Combination With HS022 and Trastuzumab®.There were 2 parts.
- Trial name
- NCT06107790
- Testing
- HS022, Trastuzumab, Vinorelbine Bitartrate
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Metastatic Breast Cancer
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to demonstrate that SYD985 [(vic-)trastuzumab duocarmazine] is superior to physician's choice in prolonging progression free survival.
- Trial name
- TULIP (NCT03262935)
- Testing
- (vic-)trastuzumab duocarmazine, Physician's choice
- Where
- 90 sites in United States, Belgium and 9 more
- Volunteers
- 437 people
- Sponsor
- Byondis B.V.
Breast Cancer Metastatic
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong…
- Trial name
- NCT04262804
- Testing
- Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine)
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which…
- Trial name
- NCT01454934
- Testing
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 540 people
- Sponsor
- Eisai Inc.
HER2-positive Advanced Breast Cancer
DP303c in Patients With HER2-positive Advanced Breast Cancer
This is a study of DP303c in patients with HER2-positive advanced breast cancer.
- Trial name
- NCT05901935
- Testing
- DP303c, Trastuzumab, Vinorelbine Tartrate
- Volunteers
- 420 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors.
- Trial name
- NCT03386721
- Testing
- simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine
- Where
- 44 sites in United States, Belgium and 13 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Malignant Tumor of the Breast
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
This randomized phase 2 study will seek to determine the effectiveness of chemotherapy (physician's choice of vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or capecitabine) plus trastuzumab vs chemotherapy…
- Trial name
- NCT02229149
- Testing
- Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- US Oncology Research
Advanced Cancer, Metastatic Cervical Cancer
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with…
- Trial name
- NCT04943627
- Testing
- Balstilimab (BAL), Topotecan, Vinorelbine
- Where
- 3 sites in United States, Armenia
- Sponsor
- Agenus Inc.
Lung Adenocarcinoma
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
This study will determine the highest dose of L-DOS47 that can be given in combination with vinorelbine/cisplatin, evaluate safety and tolerability of L-DOS47 when given in combination with vinorelbine/cisplatin, and assess how…
- Trial name
- NCT03891173
- Testing
- L-DOS47, Cisplatin, Vinorelbine
- Where
- 4 sites in Poland, Ukraine
- Volunteers
- 9 people
- Sponsor
- Helix BioPharma Corporation
Breast Cancer
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free…
- Trial name
- ASCENT (NCT02574455)
- Testing
- Sacituzumab govitecan, Eribulin, Capecitabine
- Where
- 230 sites in United States, Belgium and 5 more
- Volunteers
- 529 people
- Sponsor
- Gilead Sciences
Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal…
- Conditions
- Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
- Trial name
- CheckMate 9TN (NCT03770299)
- Testing
- Nivolumab, Vinorelbine, Gemcitabine
- Sponsor
- Bristol-Myers Squibb
Metastatic Triple Negative Breast Cancer
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
In this study, participants with metastatic triple negative breast cancer (mTNBC) will be randomly assigned to receive either single agent pembrolizumab or single agent chemotherapy chosen by the treating physician (Treatment of…
- Trial name
- NCT02555657
- Testing
- pembrolizumab, capecitabine, eribulin
- Volunteers
- 622 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy
This is a phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy.
- Trial name
- NCT02925000
- Testing
- TLC178
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 46 people
- Sponsor
- Taiwan Liposome Company
Non-small Cell Lung Cancer
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small…
- Trial name
- EVIDENCE (NCT02448797)
- Testing
- Icotinib, Chemotherapy
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Mesothelioma
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage IV mesothelin overexpressing malignant pleural mesothelioma (MPM).
- Trial name
- NCT02610140
- Testing
- Anetumab ravtansine (BAY94-9343), Vinorelbine
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 248 people
- Sponsor
- Bayer
Lung Cancer
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054197
- Testing
- gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma